文献速递毛发、甲与色素性疾病

1.5%鲁索替尼乳膏治疗斑秃:2部分双盲随机对照2期研究

Ruxolitinib cream for the treatment of patients with alopecia areata: A 2-part, double-blind, randomized, vehicle-controlled phase 2 study.
PubMed 文献 · J Am Acad Dermatol · 2019-10-14

该研究评估1.5%鲁索替尼乳膏治疗斑秃的疗效与安全性。A部分为开放标签24周研究,B部分为双盲、赋形剂对照24周研究。B部分显示鲁索替尼乳膏与赋形剂相比,在SALT评分改善50%的毛发再生方面无显著差异,未发现显著安全性问题。

要点

  • 1.5%鲁索替尼乳膏在B部分未显示优于赋形剂的毛发再生效果
  • 研究未发现1.5%鲁索替尼乳膏的显著安全性问题
  • A部分结果曾提示潜在疗效,但B部分未证实

核心结论

  • 1.5%鲁索替尼乳膏对斑秃患者无显著疗效。

研究设计与样本

  • 两部分研究:A部分为开放标签24周研究,纳入脱发25%至99%的患者;B部分为双盲、赋形剂对照24周研究,纳入脱发25%至100%的患者。

主要发现

  • B部分中,1.5%鲁索替尼乳膏组与赋形剂组在SALT评分改善50%的毛发再生方面无显著差异。
  • A部分结果提示1.5%鲁索替尼乳膏可能有效。
  • 1.5%鲁索替尼乳膏未出现显著安全性问题。

关键数值与推荐

  • 疗效评估基于SALT评分改善50%的毛发再生。
  • 纳入标准为SALT评分脱发至少25%。

临床怎么用

  • 1.5%鲁索替尼乳膏不推荐用于斑秃治疗。

局限性

  • 研究仅使用单一浓度的鲁索替尼乳膏。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There are currently no treatments for alopecia areata (AA) that are universally effective or approved by the US Food and Drug Administration. Oral ruxolitinib has shown efficacy in extensive AA. Ruxolitinib cream would potentially avoid systemic adverse effects. OBJECTIVE: To assess the efficacy and safety of 1.5% ruxolitinib cream in patients with AA who had at least 25% hair loss by Severity of Alopecia Tool score. METHODS: This was a 2-part study. Part A was an open-label, 24-week study of 1.5% ruxolitinib cream in patients with 25% to 99% hair loss followed by a 24-week extension period. Part B was a double-blind, vehicle-controlled, 24-week study of 1.5% ruxolitinib cream in patients with 25% to 100% hair loss, followed by a crossover to ruxolitinib cream in the vehicle group for 24 weeks and additional treatment time for the ruxolitinib cream group. RESULTS: Although Part A results suggested potential efficacy of 1.5% ruxolitinib cream, there was no significant difference in hair regrowth based on 50% improvement in Severity of Alopecia Tool scores between patients receiving 1.5% ruxolitinib cream and vehicle in part B. There were no significant safety issues with 1.5% ruxolitinib cream. LIMITATIONS: Single strength of ruxolitinib cream. CONCLUSIONS: The 1.5% ruxolitinib cream did not have a significant effect in patients with AA.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Olsen EA, Kornacki D, Sun K, et al. Ruxolitinib cream for the treatment of patients with alopecia areata: A 2-part, double-blind, randomized, vehicle-controlled phase 2 study. J Am Acad Dermatol. 2019. PMID: 31622643. doi:10.1016/j.jaad.2019.10.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。